Key result
Optimized thrombolytic therapy and third-generation plasminogen activators may expand eligibility and improve reperfusion in acute myocardial infarction.
Optimized thrombolytic regimens and third-generation plasminogen activators hold potential for earlier and more complete reperfusion in acute myocardial infarction.
May expand thrombolysis options where PCI access is delayed; leaves open need for randomized trials versus primary PCI.
The ability of thrombolytic therapy to lower mortality in patients with acute myocardial infarction was first demonstrated in 1986 by the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. In the ensuing 10 years, large efforts have been undertaken to develop more effective and safer thrombolytic agents. In addition, the value of adjunctive agents influencing thrombotic and thrombolytic processes was demonstrated, and newer agents are under active investigation. This review focuses on theoretical and practical aspects of optimizing thrombolytic therapy and on genetically engineered third generation plasminogen activators. Optimized thrombolytic therapy may make this form of therapy available to patients who are currently considered ineligible, and it will lead to earlier, more complete reperfusion of infarct-related coronary arteries. The benefits and risks of optimized thrombolytic regimens relative to those of mechanical reperfusion strategies will require constant reassessment while both forms of treatment develop.
No takes yet. Share an insight, caveat, or question.
Bode et al. (1996) conducted a review in acute myocardial infarction. thrombolytic therapy was evaluated. Optimized thrombolytic therapy and third-generation plasminogen activators may expand eligibility and improve reperfusion in acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: